Infliximab for intensification of primary therapy for Kawasaki disease: A phase 3 randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 383, Issue 9930, 2014, Pages 1731-1738

  Tremoulet, Adriana H ^a,c   Jain, Sonia ^b   Jaggi, Preeti ^d   Jimenez Fernandez, Susan ^a,c   Pancheri, Joan M ^c   Sun, Xiaoying ^b   Kanegaye, John T ^a,c   Kovalchin, John P ^d   Printz, Beth F ^a,c   Ramilo, Octavio ^d   Burns, Jane C ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; PLACEBO; DIPHENHYDRAMINE; PARACETAMOL;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY TEMPERATURE; CHILD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; INFANT; INTENTION TO TREAT ANALYSIS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT CORONARY ARTERY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY; NEUTROPHIL COUNT; NEWBORN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGHT CORONARY ARTERY; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; ABDOMINAL PAIN; BLOOD CLOTTING DISORDER; DRUG EFFECT; ELECTROLYTE DISTURBANCE; HEADACHE; HEPATITIS; HYPERTENSION; RASH; SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ASPIRIN; CHILD; CHILD, PRESCHOOL; CORONARY VESSELS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900792487     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62298-9     Document Type: Article

References (33)

1. Burns JC, Capparelli EV, Brown J.A., Newburger JW, Glode MP, and the US/Canadian Kawasaki Syndrome Study Group. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998; 17: 1144-48.
2. Tremoulet AH, Best BM, Song S, et al Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153: 117-21.
3. Furukawa S, Matsubara T, Jujoh K., et al Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 1988; 48: 247-51.
4. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56: 29-36.
5. Oharaseki T, Yokouchi Y, Yamada H., et al The role of TNF-alpha in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod Rheumatol 2013; published online March 26. DOI:10.1007/s10165-013-0865-4.
6. Choueiter NF, Olson AK, Shen D.D., Portman MA Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010; 157: 960-66. e1.
7. Burns JC, Mason WH, Hauger S.B., et al Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146: 662-67.
8. Burns JC, Best BM, Mejias A, et al Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008; 153: 833-38.
9. Son MB, Gauvreau K, Burns J.C., et al Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011; 158: 644-49.e1.
10. Newburger JW, Takahashi M, Gerber M.A., et al, and the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, and the Council on Cardiovascular Disease in the Young, and the American Heart Association, and the American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-71.
11. Gunn L, Nechyba C. The Harriet Lane Handbook, 16th edn. Philadelphia: Mosby, 2002.
12. Margossian R, Lu M, Minich L.L., et al, and the Pediatric Heart Network Investigators. Predictors of coronary artery visualization in Kawasaki disease. J Am Soc Echocardiogr 2011; 24: 53-59.
13. de Zorzi A., Colan SD, Gauvreau K, Baker A.L., Sundel RP, Newburger JW Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133: 254-58.
14. Okada Y, Shinohara M, Kobayashi T., et al, and the Gunma Kawasaki Disease Study Group. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003; 143: 363-67.
15. Sundel RP, Baker AL, Fulton D.R., Newburger JW Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142: 611-16.
16. Inoue Y, Okada Y, Shinohara M., et al A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-41.
17. Newburger JW, Sleeper LA, McCrindle B.W., et al, and the Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356: 663-75.
18. Ogata S, Ogihara Y, Honda T., Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 2012; 129: e17-23.
19. Kobayashi T, Saji T, Otani T., et al, and the RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613-20.
20. Chen S, Dong Y, Yin Y., Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013; 99: 76-82.
21. Sleeper LA, Minich LL, McCrindle B.M., et al Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158: 831-35. e3.
22. Dallaire F, Fournier A, Breton J., Nguyen TD, Spigelblatt L, Dahdah N. Marked variations in serial coronary artery diameter measures in Kawasaki disease: a new indicator of coronary involvement. J Am Soc Echocardiogr 2012; 25: 859-65.
23. Franco A, Shimizu C, Tremoulet A.H., Burns JC Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity 2010; 43: 317-24.
24. Burns JC, Song Y, Bujold M., et al Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 2013; 174: 337-44.
25. Boschetti G, Nancey S, Sardi F., Roblin X, Flourié B, Kaiserlian D. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 160-70.
26. Nadkarni S, Mauri C, Ehrenstein MR Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007; 204: 33-39.
27. Bongartz T, Sutton AJ, Sweeting M.J., Buchan I., Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
28. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-10.
29. Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome. J Pediatr 2006; 149: 426.
30. Song MS, Lee SB, Sohn S, et al Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 2010; 40: 334-38.
31. Jimenez-Fernandez S.G., Tremoulet AH Infliximab treatment of pancreatitis complicating acute Kawasaki disease. Pediatr Infect Dis J 2012; 31: 1087-89.
32. Mori M, Imagawa T, Hara R., et al Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 2012; 39: 864-67.
33. Son MB, Gauvreau K, Ma L., et al Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124: 1-8.